Thirty-nine miners who had been trapped underground in northern Ontario have returned to the surface safe, the company that owns the mine said Wednesday.
Vale said the rescue operation at Totten Mine near Sudbury, Ont., is complete.
“I’d like to congratulate our rescue team,” said Vale CEO Eduardo Bartolomeo in a statement.
“Bringing our 39 employees home safe and healthy was our top priority and we’re glad that our emergency plans and procedures worked to deliver that outcome. All the employees are safe now and deserve our deep respect for their perseverance and strong will.”
The workers became trapped in the mine on Sunday when a scoop bucket being sent underground detached and blocked the mine shaft.
Some of the miners were trapped as deep as 1,200 metres below the surface, the company said.
They had to scale a series of ladders to climb out of the mine and were helped along by a rescue crew.
The rescue operation began on Monday night.
A team of 58 responders from the company’s rescue team and the Ontario Mine Rescue agency helped the trapped workers through their long trek up the ladder system, the company said.
“This is tremendous news flowing from very difficult circumstances,” Bartolomeo said from the mine.
“All of us at Vale were focused on and committed to the safe return of our employees underground.”
Bartolomeo said the company will launch an investigation into what happened “so that the company can learn from it and take steps to ensure it never happens again.”
Vale said the workers stayed in underground “refuge stations” and had access to food, water and medicine before climbing out.
The province’s Ministry of Labour, Training and Skills Development said an inspection team will investigate the incident.
Totten Mine opened in 2014 in Worthington, Ont., and produces copper, nickel and precious metals. It employs about 200 people.
Tesla stock surges as Hertz orders 100,000 electric cars – Aljazeera.com
[unable to retrieve full-text content]
- Tesla stock surges as Hertz orders 100,000 electric cars Aljazeera.com
- Hertz to buy 100,000 Teslas for its rental fleet by next year CBC.ca
- Tesla soars on Hertz deal CNBC Television
- The Hertz-Tesla Deal Will Help Normalize Electric Cars Bloomberg
- Elon Musk Makes Tesla, Hertz and Bitcoin Memes Go Up Bloomberg
- View Full coverage on Google News
UBS logs surprise 9% rise in Q3 net profit
UBS posted a 9% rise in third-quarter net profit on Tuesday, as continued trading helped the world’s largest wealth manager to its best quarterly profit since 2015.
Its third-quarter net profit of $2.279 billion far outpaced a median estimate of $1.596 billion from a poll of 23 analysts compiled by Switzerland’s largest bank.
“Our business momentum, our focus on fueling growth, on disciplined execution and on delivering our full ecosystem to clients – all of this led to another strong quarter across all of our business divisions and regions,” Chief Executive Ralph Hamers said in a statement.
In each of the last four quarters, UBS saw double-digit percent gains in net profit as buoyant markets helped it generate higher earnings off of managing money for the rich.
From July through September, favourable market conditions, and higher lending and trading amongst its wealthy clientele, unexpectedly helped raise earnings over the bumper levels reported in the third quarter of last year.
(Reporting by Oliver Hirt and Brenna Hughes Neghaiwi; Editing by Michael Shields and Edwina Gibbs)
Analysis: Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds
Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.
The industry, which traditionally gives more to Republicans, channeled around 60% of donated campaign funds to Democrats this year. It has spent over $177 million on lobbying and campaign donations in 2021.
Nonprofit political action committees (PACs) run by Pfizer Inc and Amgen Inc and the Pharmaceutical Research and Manufacturers of America (PhRMA) were among the biggest donors, according to political spending data from OpenSecrets, formerly the Center for Responsive Politics.
Drugmakers are seeking to block laws that would give the U.S. government authority to negotiate prices for prescription medicines. Current U.S. law bars the government’s Medicare health insurance program from negotiating drug prices directly.
Many of the Democrats opposing an ambitious drug reduction bill proposed in the House of Representatives are among some of the biggest recipients of drug manufacturer lobbying funds.
They include Senators Kyrsten Sinema of Arizona, Robert Menendez of New Jersey, and Representative Scott Peters of California, OpenSecrets data covering industry donations through September of 2021 shows. In all, they have received around $1 million in pharmaceutical and health product industry donations this year.
A spokesperson for Sinema did not respond to a request for comment on the funds she has received but said the Senator supports making drugs as cheap as possible for patients.
Menendez and Peters said the donations did not influence their views. All three said they are opposed to The Lower Drug Costs Now Act, which is sponsored by Democrats in the House of Representatives and also known as H.R.3.
Menendez and Peters have advocated for alternative scaled-back drug pricing reforms that would still allow Medicare to negotiate drug prices but would lead to significantly smaller savings.
Congressman Frank Pallone of New Jersey, who is also one of the top recipients of drugmaker donations, voted in favor of H.R.3.
Sinema, who campaigned in 2018 on cutting drug prices, told the White House she opposes allowing Medicare to negotiate them. She received about $466,000 from the industry in 2021, according to OpenSecrets data.
Peters was the top recipient of pharmaceutical industry funds in the House this year at nearly $99,550, according to OpenSecrets data. A spokesperson said Peters was not influenced by lobbying money and opposed the proposed law to protect pharmaceutical industry jobs and innovation.
Drugmakers say the Democrats’ proposed drug price overhaul would undermine their ability to develop new medicines, an argument they have used whenever price cuts are discussed by politicians regardless of political party.
“Patients face a future with less hope under Congress’ current drug pricing plan,” PhRMA Chief Executive Steve Ubl said in an August statement in reference to the proposed law. PhRMA declined to comment on donating to key Democratic opponents of the bill.
The United States is an outlier as most other developed nations do negotiate drug prices with manufacturers.
Amgen did not immediately respond to requests for comment on its donations and Pfizer declined to comment.
PROSPECTS FOR REFORM
President Joe Biden has vowed to cut medicine costs, in part by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.
But prospects for major drug pricing reforms have stalled in recent weeks amid opposition from centrist Democrats including Sinema and Peters. Negotiations are ongoing, eight Democratic staffers said.
The lawmakers’ resistance comes as 83% of Americans support allowing Medicare to negotiate medicine costs, according to a Kaiser Family Foundation poll. The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.
“Members of Congress don’t always mirror the views of the public and the pharmaceutical industry is a powerful lobbying force,” said Larry Levitt, a health economist at Kaiser.
The healthcare industry is the second largest industry lobbying group in the United States behind the finance sector. It donated more than $600 million to politicians ahead of the 2020 elections.
The pharmaceutical industry has spent hundreds of millions of dollars per year to sway federal and state policy. But current Democratic leadership has the industry concerned major reforms could actually be enacted and is working harder to offer alternatives such as reducing insurance co-pays, one industry source said. “It’s been sort of a mad scramble.”
Corporations in the United States are not permitted to make direct contributions to candidates but can give money through PACs. Most corporate PACs, including Pfizer’s and Amgen’s, are run by company managers and employees.
Democrats and some drug price experts say the Lower Drug Costs Now Act could save U.S. taxpayers and consumers billions annually with relatively minor impact on innovation.
A House Oversight and Reform Committee report showed that top drugmakers have spent around $50 billion more on share buybacks and dividends than research and development between 2016 and 2020.
Lovisa Gustafsson, a healthcare policy analyst at the Commonwealth Fund, a non-profit healthcare advocacy group, said, “There are other ways that we can incentivize innovation, aside from just paying huge margins for pharmaceutical companies.”
(Reporting by Ahmed Aboulenein in Washington and Carl O’Donnell in New York; Editing by Caroline Humer and Bill Berkrot)
Swiss National Bank Warns of Risks With Green Economy Push – Bloomberg
Saint John saw record real estate prices. So why did assessments barely budge, mayor asks – CBC.ca
Sask. to offer monoclonal antibodies to some COVID-19 patients – Flipboard
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
Media20 hours ago
Media Advisory: Minister Abbott to Introduce New Accessibility Legislation – News Releases – Government of Newfoundland and Labrador
Art15 hours ago
Knitting for Guelph's Art Not Shame: 3 things to know about the organization and fundraiser – GuelphMercury.com
Science21 hours ago
New nuclear reactors can help France become carbon neutral by 2050 -RTE
Investment21 hours ago
Mastercard expands cryptocurrency services with wallets, loyalty rewards
Science21 hours ago
World strives to limit damage as greenhouse gas levels hit record
News21 hours ago
Huawei CFO Meng Wanzhou returns to work in Shenzhen, after extradition drama – Global Times
Economy22 hours ago
Explainer: Climate change: what are the economic stakes?
News22 hours ago
Coronavirus: What's happening in Canada and around the world on Monday – CBC.ca